NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its two lead product candidates, include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland.
$1.26 -0.02 (-1.37%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Switzerland
Country of incorporation:
IPO date: 01/28/2021
Outstanding shares: 27,453,603
Average volume: 84,519
Market cap: $35,140,612
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%